F 14512

Drug Profile

F 14512

Alternative Names: 14512; F14512

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Acetamides; Antineoplastics; Heterocyclic compounds with 4 or more rings
  • Mechanism of Action Apoprotein stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 17 Feb 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, In the elderly) in Italy (IV)
  • 15 Oct 2014 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, In the elderly) in Spain (IV)
  • 19 Nov 2009 Phase-I clinical trials in Haematological malignancies in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top